Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme & Protein Therapy – 2019 – ResearchAndMarkets.com – Yahoo Finance

The "Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme, and Protein Therapy" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) encompasses innovation insights across biosimilars, gene therapy, microbiome, robotics, ribozyme, and protein therapy. The TOE also provides technological analysis for recent developments in animal protein applications, microbiome, and cell cultures.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Recent Advancements in the Biotech Industry

Key Industry Contacts

For more information about this report visit https://www.researchandmarkets.com/r/2q5ocu

View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005525/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

More:
Innovations in Gene Therapy, Microbiome, Robotics, Ribozyme & Protein Therapy - 2019 - ResearchAndMarkets.com - Yahoo Finance

Related Post

Recommendation and review posted by Alexandra Lee Anderson

Both comments and pings are currently closed.

Comments are closed.